Laquinimod, a once-daily oral drug in development for the treatment of relapsing–remitting multiple sclerosis

References

• Stadelmann C. Multiple sclerosis as a neurodegenerative disease: pathology, mechanisms and therapeutic implications. Curr. Opin. Neurol.24(3), 224–229 (2011).
   PubMed Web of Science ®Google Scholar
• Lassmann H. Pathophysiology of inflammation and tissue injury in multiple sclerosis: what are the targets for therapy. J. Neurol. Sci.306(1–2), 167–169 (2011).
   PubMedGoogle Scholar
• Rieckmann P, Toyka KV. Escalating immunotherapy of multiple sclerosis. Austrian–German–Swiss multiple sclerosis therapy consensus group (MSTCG). Eur. Neurol.42(3), 121–127 (1999).
   PubMedGoogle Scholar
• Nicholas R, Giannetti P, Alsanousi A, Friede T, Muraro PM. Development of oral immunomodulatory agents in the management of multiple sclerosis. Drug Des. Devel. Ther.5, 255–274 (2011).
   PubMed Web of Science ®Google Scholar
• Conway D, Cohen JA. Emerging oral therapies in multiple sclerosis. Curr. Neurol. Neurosci. Rep.10(5), 381–388 (2010).
   PubMedGoogle Scholar
• Cohen JA, Chun J. Mechanisms of fingolimod’s efficacy and adverse effects in multiple sclerosis. Ann. Neurol.69(5), 759–777 (2011).
   PubMed Web of Science ®Google Scholar
• Mehling M, Brinkmann V, Antel J et al. FTY720 therapy exerts differential effects on T-cell subsets in multiple sclerosis. Neurology71(16), 1261–1267 (2008).
   PubMed Web of Science ®Google Scholar
• Kappos L, Radue EW, O’Connor P et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N. Engl. J. Med.362(5), 387–401 (2010).
   PubMed Web of Science ®Google Scholar
• Cohen JA, Barkhof F, Comi G et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N. Engl. J. Med.362, 402–415 (2010).
   PubMed Web of Science ®Google Scholar
• GILENYA®, package insert. Novartis Pharma Stein AG, Stein, Switzerland (2010).
   Google Scholar
• Khari B, Barkhof F, Comi G et al.; TRANSFORMS Study Group. Comparison of fingolimod with interferon-β-1a in relapsing–remitting multiple sclerosis: a randomized extension of the TRANSFORMS study. Lancet Neurol.10(6), 520–529 (2011).
   PubMedGoogle Scholar
• Hohlfeld R, Barkhof F, Polman C. Future clinical challenges in multiple sclerosis: relevance to sphingosine 1-phosphate receptor modulator therapy. Neurology76, S28–S37 (2011).
   PubMedGoogle Scholar
• Miller A, O’Connor P, Wolinsky JS et al. Clinical and MRI outcomes from a Phase III trial (TEMSO) of oral teriflunomide in multiple sclerosis with relapses. Program and Abstracts of the 63rd Annual Meeting of the American Academy of Neurology. Honolulu, HI, USA, 9–16 April 2011 (Abstract 545).
   Google Scholar
• Warnke C, Meyer zu Hörste G, Hartung HP, Stüve O, Kieseier BC. Review of teriflunomide and its potential in the treatment of multiple sclerosis. Neuropsychiatr. Dis. Treat.5, 333–340 (2009).
   PubMed Web of Science ®Google Scholar
• Claussen MC, Korn T. Immune mechanisms of new therapeutic strategic in MS – teriflunomide. Clin. Immunol.142(1), 49–56 (2012).
   PubMed Web of Science ®Google Scholar
• Linker RA, Lee DH, Ryan S et al. Fumaric acid esters exert neuroprotective effects in neuroinflammtion via activation of the Nrf2 antioxidant pathway. Brain134(Pt 3), 678–692 (2011).
   PubMed Web of Science ®Google Scholar
• Jonsson S, Andersson G, Fex T et al. Synthesis and biological evaluation of new 1,2-dihydro-4-hydroxy-2-oxo-3-quinolinecarboxamides for treatment of autoimmune disorders: structure–activity relationship. J. Med. Chem.47(8), 2075–2088 (2004).
   PubMed Web of Science ®Google Scholar
• Polman C, Barkhof F, Sandberg-Wollheim M, Linde A, Nordle O, Nederman T. Treatment with laquinimod reduces development of active MRI lesions in relapsing MS. Neurology64(6), 987–991 (2005).
   PubMed Web of Science ®Google Scholar
• Comi G, Pulizzi A, Rovaris M et al. Effect of laquinimod on MRI-monitored disease activity in patients with relapsing–remitting multiple sclerosis: a multicentre, randomized, double-blind, placebo-controlled Phase IIb study. Lancet371(9630), 2085–2092 (2008).
   PubMed Web of Science ®Google Scholar
• Comi G, Jeffery D, Kappos L et al. Placebo-controlled trial of oral laquinimod for multiple sclerosis. N. Engl. J. Med.366(11), 1000–1009 (2012).
   PubMed Web of Science ®Google Scholar
• Brück W, Wegner C. Insight into the mechanism of laquinimod action. J. Neurol. Sci.306(1–2), 173–179 (2011).
   PubMed Web of Science ®Google Scholar
• Steinman L, Zamvil SS. Virtues and pitfalls of EAE for the development of therapies for multiple sclerosis. Trends Immunol.26(11), 565–571 (2005).
   PubMed Web of Science ®Google Scholar
• Brunmark C, Runstrom A, Ohlsson L et al. The new orally active immunoregulator laquinimod (ABR-215062) effectively inhibits development and relapses of experimental autoimmune encephalomyelitis. J. Neuroimmunol.130(1–2), 163–172 (2002).
   PubMed Web of Science ®Google Scholar
• Yang JS, Xu LY, Xiao BG, Hedlund G, Link H. Laquinimod (ABR-215062) suppresses the development of experimental autoimmune encephalomyelitis, modulates the Th1/Th2 balance and induces the Th3 cytokine TGF-β in Lewis rats. J. Neuroimmunol.156(1–2), 3–9 (2004).
   PubMed Web of Science ®Google Scholar
• Wegner C, Stadelmann C, Pförtner R et al. Laquinimod interferes with migratory capacity of T cells and reduces IL-17 levels, inflammatory demyelination and acute axonal damage in mice with experimental autoimmune encephalomyelitis. J. Neuroimmunol.227(1–2), 133–143 (2010).
   PubMed Web of Science ®Google Scholar
• Zou LP, Abbas N, Volkmann I et al. Suppression of experimental autoimmune neuritis by ABR-215062 is associated with altered Th1/Th2 balance and inhibited migration of inflammatory cells into the peripheral nerve tissue. Neuropharmacology42(5), 731–739 (2002).
   PubMed Web of Science ®Google Scholar
• AA32235. Laquinimod sodium: 4-week oral (gavage) immunotoxicity study in the Sprague Dawley rat. MDS Pharma Services, France (2007) (Final Report).
   Google Scholar
• HeartTx/Teva-LQ/Jun06. Laquinimod does not result in prolongation of heart survival in a model of allogeneic heterotopic rat heart transplants. Teva Pharmaceutical Industries, Israel (2006) (Final Report).
   Google Scholar
• Gurevich M, Gritzman T, Orbach R, Tuller T, Feldman A, Achiron A. Laquinimod suppress antigen presentation in relapsing–remitting multiple sclerosis: in vitro high-throughput gene expression study. J. Neuroimmunol.221(1–2), 87–94 (2010).
   PubMed Web of Science ®Google Scholar
• Sättler MB, Togni M, Gadjanski I et al. Strain-specific susceptibility for neurodegeneration in a rat model of autoimmune optic neuritis. J. Neuroimmunol.193(1–2), 77–86 (2008).
   PubMedGoogle Scholar
• Sühs KW. Effects of laquinimod on axon degeneration in autoimmune optic neuritis. Mult. Scler.13, S7–S273, P835 (2007).
   PubMedGoogle Scholar
• Thöne J, Ellrichmann G, Seubert S et al. Modulation of autoimmune demyelination by laquinimod via induction of brain-derived neurotrophic factor. Am. J. Pathol.180(1), 267–274 (2012).
   PubMed Web of Science ®Google Scholar
• Tuvesson H, Hallin I, Ellman M et al.In vitro metabolism and in vivo pharmacokinetics of quinoline 3-carboxamide derivatives in various species. Xenoboiotica35(3), 293–304 (2005).
   PubMed Web of Science ®Google Scholar
• Tuvesson H, Hallin I, Persson R et al. Cytochrome P450 3A4 is the major enzyme responsible for the metabolism of laquinimod, a novel immunomodulator. Drug Metab. Dispos.33(6), 866–872 (2005).
   PubMed Web of Science ®Google Scholar
• Comi G, Abramsky O, Arbizu T et al. Oral laquinimod in patients with relapsing–remitting multiple sclerosis: 36 weeks double-blind active extension of the multicenter, randomized, double-blind, parallel-group placebo-controlled study. Mult. Scler.16(11), 1360–1366 (2010).
   PubMed Web of Science ®Google Scholar
• Comi G, Abramsky O, Arbizu T et al. Long-term open extension of oral laquinimod in patients with relapsing multiple sclerosis shows favorable safety and sustained low relapse rate and MRI activity. Presented at: The 25th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. Düsseldorf, Germany, 9–12 September 2009.
   Google Scholar
• Thöne J, Gold R. Laquinimod: a promising oral medication for the treatment of relapsing–remitting multiple sclerosis. Expert Opin. Drug Metab. Toxicol.7(3), 365–370 (2011).
   PubMed Web of Science ®Google Scholar
• Vollmer TL, Sörensen PS, Arnold DL; on behalf of the BRAVO study group. A placebo-controlled and active comparator Phase III trial (BRAVO) for relapsing–remitting multiple sclerosis: Presented at: The 27th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. Amsterdam, The Netherlands, 19–22 October 2011.
   Google Scholar
• Kurtzke JF. Rating neurological impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS). Neurology33, 1444–1452 (1983).
   PubMed Web of Science ®Google Scholar
• Janssen HL, Meinardi JR, Vleggaar FP et al. Factor V leiden mutation, prothrombin gene mutation, and deficiencies in coagulation inhibitors associated with Budd–Chiari syndrome and portal vein thrombosis: results of a case–control study. Blood96(7), 2364–2368 (2000).
   PubMed Web of Science ®Google Scholar
• Deltenre P, Denninger MH, Hillaire S et al. Factor V leiden related Budd–Chiari syndrome. Gut48(2), 264–268 (2001).
   PubMedGoogle Scholar